Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis

Nephrology Dialysis Transplantation

Volumn 19, Issue 6, 2004, Pages 1552-1558

  Frank, Rolf Dario ^a   Brandenburg, Vincent M ^a   Lanzmich, Regina ^a   Floege, Jürgen ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Activated clotting time; Haemodialysis; Low molecular weight heparin; Monitoring

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ANALYTICAL EQUIPMENT; ANTICOAGULATION; ARTICLE; BIOASSAY; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG MECHANISM; DRUG MONITORING; FEMALE; HEALTH CARE COST; HEMODIALYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; LABORATORY TEST; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; TIME;

ADULT; AGED; ANTICOAGULANTS; DALTEPARIN; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; POINT-OF-CARE SYSTEMS; RENAL DIALYSIS; WHOLE BLOOD COAGULATION TIME;

EID: 2942737097     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh203     Document Type: Article

References (23)

1. Kraatz G, Lopot F. Messung der aktivierten Vollblutgerinnung als Kontrollparameter für die Heparindosierung bei Hä modialyse. Z Urol Nephrol 1984; 77: 465-471
2. Stenbjerg S, Berg E, Albrechtsen OK. Evaluation of the activated whole blood clotting time (ACT) in vitro. Scand J Haematol 1979; 23: 239-244
3. Lord H, Jean N, Dumont M, Kassis J, Leblanc M. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol 2002; 22: 58-66
4. Borm JJJ, Krediet R, Sturk A, ten Cate JW. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study. Haemostasis 1986; 16 [Suppl. 2]: 59-68
5. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496-500
6. Schmitt Y and Schneider H. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993; 8: 438-442
7. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335
8. Schrader J, Stibbe W, Armstrong VW et al. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890-896
9. Baumann D, Frühsorger A, Glass W, Zielke E. Bolusapplikation von Fragmin zur Antikoagulation in der Hämodialyse. Nieren- u Hochdruckkrankheiten 1991; 20: 36-40
10. Ljungberg B, Blombäck M, Johnsson H, Lins LE. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1986; 27: 31-35
11. Hafner G, Swars H, Ehrenthal W, Schinzel H, Weilemann LS, Prellwitz W. The control of anti-coagulation in acute dialyses with sensitive laboratory parameters. Scand J Clin Lab Invest 1992; 52: 289-296
12. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Fauchald P, Brosstad F. A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 1999; 14: 1943-1947
13. Briel RC, Zielke E, Zwirner M. Untersuchungen zur Korrelation der anti-Faktor Xa-Aktivität von niedermolekularem Heparin (Fragmin) und der aktivierten Vollblutgerinnungszeit im AC-Tester. Ärztl Lab 1987; 33: 237-240
14. Schulz W, Deuber HJ, Günthner R, Ohrisch G, Eichhorn M, Werthmann G. Aktueller sand des einsatzes von niedermolekularem heparin in der hämodialyse-therapie. Nieren- u Hochdruckkrankheiten 1995; 24: 187-197
15. Greiber S, Weber U, Galle J, Brämer P, Schollmeyer P. Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular weight heparin in hemodialysis. Nephron 1997; 76: 15-19
16. Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low molecular weight heparin? Am Heart J 2001; 142: 590-593
17. Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, Richard MF. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003; 41: 394-402
18. Mori M, Yoshitake S, Kitano T, Oda S, Noguchi T. Measurement of whole blood factor Xa-activated clotting time during hemodialysis with low-molecular-weight heparin. J Anesth 1998; 12: 130-132
19. Koerber JM, Smythe MA, Begle RL, Mattson JC, Kershaw BP, Westley SJ. Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotherapy 1999; 19: 922-931
20. Smythe A, Koerber JM, Nowak SN, Mattson JC, Begle RL, Westley SJ, Balasubramaniam M. Correlation between activated clotting time and activated partial thromboplastin times. Ann Pharmacother 2002; 36: 7-11
21. Bommer J, Schwab M. Bedside testing with the new CoaguChek Pro activated clotting time assay in dialysis. Artif Organs 2002; 26: 387-90
22. Ambrose JA, Hawkey M, Badimon JJ et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol 2000; 86: 150-152
23. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26 [Suppl. 1]: 31-38